Thrombin Inhibitor Market, By Type, By Application (Deep Vein Thrombosis, Pulmonary Embolism, Atrial Fibrillation, and Others ), By Geography

The global thrombin inhibitor market is estimated to be valued at US$ 30.75 billion in 2023 and is expected to reach US$ 46.85 billion by 2030, growing at a CAGR of 6.2% during the forecast period of 2023-2030.

Figure 1. Global Thrombin Inhibitor Market Share (%), by Region, 2023

Thrombin inhibitors are anticoagulants (or are a class of medication that act as anticoagulants) that bind to and inhibit the activity of thrombin, and therefore prevent blood clot formation. They are used to prevent arterial and venous thrombosis, as well as prevent and treat deep vein thrombosis and as prophylaxis in atrial fibrillation to avoid thromboembolism.

The conditions treated with thrombin inhibitors are; Acute Coronary Syndrome, Blood clots in heart, Heparin-induced thrombocytopenia (HIT), Venous thromboembolism (VTE), Atrial Fibrillation (Afib), Deep vein thrombosis (DVT), Pulmonary Embolism.

Direct thrombin inhibitor drugs that healthcare providers currently use include; Argatroban (IV injection), Bivalirudin (IV injection), Dabigatran (pill form).

Market Dynamics:

The increasing prevalence/incidence of deep vein thrombosis (DVT), pulmonary embolism (PE), and atrial fibrillation (AF), a rise in demand for safe and effective treatment (due to increasing awareness among people worldwide), increase in research and development (R&D), and introduction of novel anticoagulants are major factors expected to propel the growth of the global thrombin inhibitor market.

For instance, in June 2018, Mylan N.V. announced the U.S. launch of Bivalirudin for Injection, a generic version of Angiomax. The product, 250 mg single-dose vial, is a direct thrombin inhibitor indicated for use as an anticoagulant in patients. Mylan is offering Bivalirudin to its hospital and institutional customers after an Abbreviated New Drug Application (ANDA) for the product was approved by the U.S. Food and Drug Administration (FDA).

Key features of the study:

• This report provides an in-depth analysis of the global thrombin inhibitor market, and provides market size (US$ Billion) and compound annual growth rate (CAGR %) for the forecast period (2023-2030)
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global thrombin inhibitor market based on the following parameters such as company highlights, product portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Eisai Co., Ltd., Merck & Co., Inc., Novartis International AG, GlaxoSmithKline plc, AbbVie Inc., Portola Pharmaceuticals, Inc., CSL Behring, Johnson & Johnson, Sanofi S.A., Bayer AG, Pfizer Inc., Bristol Myers Squibb, Boehringer Ingelheim GmbH, Daiichi Sankyo Company, and Aspen Pharmacare Holdings Limited, among others
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global thrombin inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global thrombin inhibitor market

Detailed Segmentation:

• By Type:
  • Direct Thrombin Inhibitors
  • Indirect Thrombin Inhibitors
• By Application:
  • Deep Vein Thrombosis (DVT)
  • Pulmonary Embolism (PE)
  • Atrial Fibrillation (AF)
  • Others (Stroke Prevention, Acute Coronary Syndrome, etc.)
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Eisai Co., Ltd.
  • Merck & Co., Inc.
  • Novartis International AG
  • GlaxoSmithKline plc
  • AbbVie Inc.
  • Portola Pharmaceuticals, Inc.
  • CSL Behring
  • Johnson & Johnson
  • Sanofi S.A.
  • Bayer AG
  • Pfizer Inc.
  • Bristol Myers Squibb
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Company
  • Aspen Pharmacare Holdings Limited